外科植入Melody瓣膜于肺动脉位置的经验与结局
该回顾性研究纳入2009至2019年在波士顿儿童医院接受外科Melody瓣膜植入的23例患者,评估术后瓣膜功能、再干预率和死亡率。结果显示早期结果可接受,无急性肺动脉反流,但部分患者需经导管或外科再干预,5年免于Melody相关再手术率为83%。
要点
- 外科Melody瓣膜植入在年轻患者中早期结果可接受
- 经导管再干预可扩张瓣膜以适应生长
- 5年免于Melody相关再手术率为83%
核心结论
- Melody瓣膜可外科植入年轻患者右室流出道,早期结果可接受,且可通过经导管再干预扩张以适应生长。
研究设计与样本
- 回顾性收集2009至2019年波士顿儿童医院23例外科Melody瓣膜植入患者的资料。
主要发现
- 中位年龄1.7岁(范围2个月至6岁),12例(52%)年龄大于2岁。
- 诊断法洛四联症15例(65%),15例(65%)有既往右室流出道手术史。
- 无患者出现急性肺动脉反流,1例出院前需经导管右室流出道再干预。
- 中位随访3.7年(范围0.02至8.7年),2例出现中度或以上肺动脉反流。
- 3例(13%)因Melody特异性指征需外科瓣膜移除或替换,中位时间1.0年(范围0.6至3.7年)。
关键数值与推荐
- Melody瓣膜术前扩张至中位直径14 mm(范围10-20 mm)。
- 经导管干预平均每患者0.83±1.07次,中位时间1年(范围16天至5.4年),包括瓣膜扩张适应生长(n=10)和后续瓣中瓣替换(n=3)。
- 1年、3年和5年免于Melody驱动再手术率分别为90%、90%和83%。
临床怎么用
- 对于需肺动脉瓣替换的年轻患者,可考虑外科植入Melody瓣膜,并计划通过经导管再干预适应生长。
局限性
- 回顾性研究,样本量小(23例),随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple congenital cardiac malformations require pulmonary valve replacement and/or right ventricular outflow (RVOT) reconstruction. Pulmonary valve replacement remains challenging in children owing to the limited growth potential of prosthetic valves. We evaluated outcomes in patients undergoing surgical implantation of a Melody valve in the RVOT. METHODS: Data were retrospectively collected for 23 patients undergoing surgical Melody valve implantation at Boston Children's Hospital between 2009 and 2019. We assessed postoperative valve function, reintervention rates, and mortality. RESULTS: Median age was 1.7 years (range, 2 months to 6 years); 12 patients were aged greater than 2 years (52%). Diagnosis was tetralogy of Fallot in 15 patients (65%); 15 had a prior RVOT operation (65%). The Melody valve was dilated before surgery to a median diameter of 14 mm (range, 10-20 mm). No patients had acute pulmonary regurgitation. One required transcatheter RVOT reintervention before discharge. Median follow-up was 3.7 years (range, 0.02-8.7 years) with moderate or greater pulmonary regurgitation in 2 patients. Catheter-based interventions (mean, 0.83 ± 1.07/patient) occurred at a median of 1 year (range, 16 days to 5.4 years) and included valve expansion for somatic growth (n = 10) and subsequent valve-in-valve replacement (n = 3). Three patients (13%) required surgical valve explant or replacement at a median of 1.0 year (range, 0.6-3.7 years) for Melody-specific indications. One-, 3-, and 5-year freedom from Melody-driven reoperation was 90%, 90%, and 83%, respectively. CONCLUSIONS: The Melody valve can be surgically implanted in the RVOT of young patients with acceptable early results. These valves can be successfully dilated through transcatheter reintervention to accommodate growth.
引用
- Feins EN, Chávez M, Callahan R, et al. Experience and Outcomes of Surgically Implanted Melody Valve in the Pulmonary Position. Ann Thorac Surg. 2020. PMID: 32603706. doi:10.1016/j.athoracsur.2020.05.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。